Objective To explore the main active components, targets and mechanism of action of Ligusticum-Angelica herb pair by using the method of network pharmacology.Methods This study starts and ends from September 2020 to December 2020. The components, targets and corresponding disease datas of Ligusticum-Angelica were retrieved by Chinese medicine Systems pharmacology database and analysis platform (TCMSP) , and a "drug-component-target-disease" network was constructed, gene ontology (GO) and pathway enrichment (KEGG) were analyzed to explore the mechanism of "Ligusticum-Angelica".Results The "drug-component-target-disease" network consisted 2 drugs, 10 active components, 71 active targets and 191 diseases. The key targets involved: PTGS2, PPARG,ESR1, ADRB2, CDK2, HSP90, MAPK14, CHRM2, HTR2A, F2R, NR3C2, NOS3, etc., and key diseases included alzheimer′s disease,pain, cancer, breast cancer, cardiovascular disease, anxiety, brain damage, inflammation, prostate cancer, and solid tumors. GO enrichment analysis resulted in 237 items, including 178 items of biological process (BP), 26 items of molecular function (MF) and 33 items ofcell composition (CC) . Pathway enrichment analysis included 66 KEGG pathways, including neuroactive ligand-receptor interaction, calcium signaling pathway, pathways in cancer, serotonergic synapse etc.Conclusion Multiple components of "Ligusticum-Angelica"herb pair act on multiple targets and pathways, and have therapeutic effects on pain, cardiovascular disease, breast cancer, alzheimer′sdisease, inflammation, cancer and other diseases. |